Allakos (ALLK) Competitors $0.33 0.00 (0.00%) As of 05/15/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALLK vs. ENTA, CHRS, VIGL, CGEN, PLX, RAPT, SLN, CCCC, IFRX, and NMRAShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Enanta Pharmaceuticals (ENTA), Coherus BioSciences (CHRS), Vigil Neuroscience (VIGL), Compugen (CGEN), Protalix BioTherapeutics (PLX), RAPT Therapeutics (RAPT), Silence Therapeutics (SLN), C4 Therapeutics (CCCC), InflaRx (IFRX), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. Allakos vs. Enanta Pharmaceuticals Coherus BioSciences Vigil Neuroscience Compugen Protalix BioTherapeutics RAPT Therapeutics Silence Therapeutics C4 Therapeutics InflaRx Neumora Therapeutics Enanta Pharmaceuticals (NASDAQ:ENTA) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Do institutionals & insiders have more ownership in ENTA or ALLK? 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 13.9% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 16.1% of Allakos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor ENTA or ALLK? Enanta Pharmaceuticals received 137 more outperform votes than Allakos when rated by MarketBeat users. However, 58.84% of users gave Allakos an outperform vote while only 56.94% of users gave Enanta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnanta PharmaceuticalsOutperform Votes32056.94% Underperform Votes24243.06% AllakosOutperform Votes18358.84% Underperform Votes12841.16% Which has more risk and volatility, ENTA or ALLK? Enanta Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Is ENTA or ALLK more profitable? Allakos has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -157.57%. Enanta Pharmaceuticals' return on equity of -75.53% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-157.57% -75.53% -27.30% Allakos N/A -140.87%-86.22% Does the media refer more to ENTA or ALLK? In the previous week, Enanta Pharmaceuticals had 5 more articles in the media than Allakos. MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 0 mentions for Allakos. Enanta Pharmaceuticals' average media sentiment score of 0.95 beat Allakos' score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Enanta Pharmaceuticals Positive Allakos Neutral Which has stronger earnings & valuation, ENTA or ALLK? Enanta Pharmaceuticals has higher revenue and earnings than Allakos. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$64.46M1.95-$116.04M-$4.54-1.30AllakosN/AN/A-$185.70M-$1.32-0.25 Do analysts rate ENTA or ALLK? Enanta Pharmaceuticals currently has a consensus target price of $17.25, indicating a potential upside of 193.37%. Allakos has a consensus target price of $2.00, indicating a potential upside of 507.72%. Given Allakos' higher probable upside, analysts plainly believe Allakos is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryEnanta Pharmaceuticals beats Allakos on 12 of the 18 factors compared between the two stocks. Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.74M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.169.1226.8519.75Price / SalesN/A256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.176.436.764.50Net Income-$185.70M$144.21M$3.23B$248.32M7 Day PerformanceN/A2.25%1.71%0.48%1 Month Performance0.95%4.39%11.16%13.08%1 Year Performance-75.80%-2.71%17.17%7.36% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos4.2132 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190ENTAEnanta Pharmaceuticals3.8037 of 5 stars$5.55+5.3%$17.25+210.8%-53.6%$118.40M$66.59M-1.12160CHRSCoherus BioSciences3.6976 of 5 stars$1.02+5.3%$5.26+415.9%-62.8%$118.24M$266.96M-12.75330Analyst DowngradeVIGLVigil Neuroscience3.2166 of 5 stars$2.53+4.5%$16.25+542.3%-34.0%$118.08MN/A-1.2340Trending NewsAnalyst ForecastGap UpCGENCompugen1.7321 of 5 stars$1.32+4.8%$4.00+203.0%-25.3%$117.79M$27.86M66.0070News CoverageEarnings ReportAnalyst RevisionPLXProtalix BioTherapeutics2.1904 of 5 stars$1.46-15.1%$15.00+927.4%+40.2%$116.10M$53.40M-11.23200High Trading VolumeRAPTRAPT Therapeutics4.3839 of 5 stars$0.88+16.6%$4.00+355.2%-80.7%$116.01M$1.53M-0.3280Positive NewsAnalyst ForecastSLNSilence Therapeutics3.5243 of 5 stars$3.83+3.5%$33.83+783.4%-78.5%$114.63M$43.26M-2.44100Gap UpCCCCC4 Therapeutics2.5359 of 5 stars$1.58+7.5%$12.00+659.5%-76.4%$112.19M$35.58M-0.93150Gap UpIFRXInflaRx2.3673 of 5 stars$1.67+3.7%$8.50+409.0%+11.2%$112.11M$165,789.00-1.5560NMRANeumora Therapeutics3.0124 of 5 stars$0.69+4.5%$9.29+1,240.9%-92.0%$112.01MN/A-0.37108 Related Companies and Tools Related Companies Enanta Pharmaceuticals Competitors Coherus BioSciences Competitors Vigil Neuroscience Competitors Compugen Competitors Protalix BioTherapeutics Competitors RAPT Therapeutics Competitors Silence Therapeutics Competitors C4 Therapeutics Competitors InflaRx Competitors Neumora Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLK) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLK Stock Free ALLK Stock Alerts